arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MANNKIND CORP

MNKD
$4.10 ▲ +0.21 (+5.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Bullish
auto_awesome

Analytical Summary

MANNKIND CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.3B
Dividend Yield
Revenue Growth 22.2%
Op. Margin 11.1%
ROIC 53.3%
FCF / Share $0.04
Trailing P/E 205.0x
Price / Book
FCF Yield 1.1%
Debt / Equity -6.95
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$348.97M
↑ +22.2%
Net Income Profit after all expenses
$5.86M
↓ -78.7%
Operating Margin Operating profit as % of sales
11.1%
↓ -56.3% 59th
FCF / Share Free cash flow per share
$0.04
↓ -62.5%
Long-Term Debt Long-term obligations
$354.64M
↑ +883.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
45
Returns
33
Financial Health
82
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 35 years · 84 quarters